diagnostic tools for lung and

Diagnostic Tools for Lung and Mesothelioma Cancers to be Developed

In a recent article on Mesothelioma Cancer Diagnostic Tools, Rosetta

Genomics, Ltd. announced that it has partnered with NYU Medical Center

with the aim of developing a line of early detection diagnostic

products for lung and Mesothelioma cancers.

The early detection test will mainly target over 45 million Americans

who are at an increased risk of lung cancer due to smoking, as well as

those who have been exposed to asbestos fibers. The test will utilize

Rosetta Genomics' proprietary protocol to extract microRNAs from a

simple blood draw.

"A test that will be able to detect cancer at an early stage using a

simple blood draw will have far reaching implications on the fight

against cancer," noted Dr. Harvey Pass, Professor and Chief, Division

of Thoracic Surgery and Thoracic Oncology at NYU Medical Center.

"MicroRNAs have been shown to hold great potential as effective

biomarkers for various cancers, and I believe that NYU Medical

Center's vast experience with lung cancer and Mesothelioma, coupled

with Rosetta Genomics' expertise in the microRNA field, will allow us

to successfully advance this much needed test forward."

Posted by Mark J. at 9:44 AM